Two CANet-supported projects were awarded funding from the Accelerating Clinical Trials (ACT) Canada Consortium (RFA #5), including one led by Canadian Principal Investigator, Dr. Jason Andrade.
The fifth ACT call for proposals is designed to:
- Support ongoing, high-impact, internationally led randomized controlled trials (RCTs).
- Bring these significant trials to Canada, allowing Canadian patients to participate.
- Enable Canadian Principal Investigators and Site Investigators to contribute to an important internationally led trial and build international collaborations
It is an honour that the ACT Canada Consortium has chosen to support the EASThigh study:
Early Atrial Fibrillation Ablation for Stroke Prevention in Patients with High Comorbidity Burden.
This internationally led study, initiated by the AFNET group in Germany, builds on their previous EAST trial, which demonstrated the benefits of early rhythm control. EASThigh aims to evaluate the role of early ablation, drawing on insights from the Canadian EARLY-AF trial.
Atrial fibrillation (AF) affects nearly one million Canadians, making our country one of the highest globally in AF prevalence. Despite this, there remains a knowledge gap in determining the best initial treatment for individuals at the highest risk of AF-related complications, including death, stroke, and disability.
The EASThigh study aims to address this gap, evaluating the role of early AF ablation as a strategy to prevent adverse outcomes. By bringing this important trial to Canada, ACT funding will:
• Empower Canadian researchers to participate in and lead key components of this global trial.
• Provide Canadian patients access to cutting-edge care and treatments.
• Contribute significantly to shaping AF management worldwide.
Congratulations to Dr. Jason Andrade and his research teams, investigators, and staff.
